Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting
- Positive preclinical data was presented for the NPRL2 tumor suppressor gene
- The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models
- Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer
- ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer
Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments, announced last month that its research collaborators presented positive preclinical data for the NPRL2 gene, which is a tumor suppressor gene. The presentation was given at the 2023 American Association of Cancer Research (“AACR”) annual meeting, which took place from April 14-18, 2023, in Orlando, Florida.
The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models.
Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic effect without the risk of toxicity often associated with viral delivery systems.
“The preclinical data also provide further evidence that the ONCOPREX(R) Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA(R),” said Rodney Varner, President and Chief Executive Officer of Genprex, said (https://nnw.fm/Cm16r ). “These compelling outcomes give us further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”
The company’s cancer-fighting technologies may provide new treatment options for large cancer patient populations, such as those with lung cancer.
The company’s oncology pipeline aims to reprogram the course of cancer. Genprex is evaluating its proprietary, non-viral ONCOPREX(R) delivery system, which is believed to be the first systemic gene therapy delivery platform used for cancer in humans, in its REQORSA clinical programs.
“We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA(R) clinical oncology programs, presented before some of the world’s leading cancer researchers,” Varner also said. “The use of the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate.”
In addition to oncology, Genprex is also working on therapies for diabetes, another large patient population with limited treatment options. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes to the pancreas. The candidates in this pipeline have shown in preclinical studies in mice and non-human primates, the potential to stabilize glucose levels and reduce insulin requirements. Genprex’s R&D pipeline for diabetes includes its preclinical candidates, GPX-002 for Type 1 diabetes and GPX-003 for Type 2 diabetes.
Even with certain advancements in treatment, the quality of life remains highly compromised for many with diabetes. Diabetes gene therapies like those being developed by Genprex could hold the potential to provide long-term effectiveness and completely change the course of the disease – enhancing the quality of life for those living with the disease.
For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Positive preclinical data was presented for the NPRL2 tumor suppressor gene
- The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models
- Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer
- ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer
Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments, announced last month that its research collaborators presented positive preclinical data for the NPRL2 gene, which is a tumor suppressor gene. The presentation was given at the 2023 American Association of Cancer Research (“AACR”) annual meeting, which took place from April 14-18, 2023, in Orlando, Florida.
The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models.
Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic effect without the risk of toxicity often associated with viral delivery systems.
“The preclinical data also provide further evidence that the ONCOPREX(R) Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA(R),” said Rodney Varner, President and Chief Executive Officer of Genprex, said (https://nnw.fm/Cm16r ). “These compelling outcomes give us further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”
The company’s cancer-fighting technologies may provide new treatment options for large cancer patient populations, such as those with lung cancer.
The company’s oncology pipeline aims to reprogram the course of cancer. Genprex is evaluating its proprietary, non-viral ONCOPREX(R) delivery system, which is believed to be the first systemic gene therapy delivery platform used for cancer in humans, in its REQORSA clinical programs.
“We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA(R) clinical oncology programs, presented before some of the world’s leading cancer researchers,” Varner also said. “The use of the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate.”
In addition to oncology, Genprex is also working on therapies for diabetes, another large patient population with limited treatment options. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes to the pancreas. The candidates in this pipeline have shown in preclinical studies in mice and non-human primates, the potential to stabilize glucose levels and reduce insulin requirements. Genprex’s R&D pipeline for diabetes includes its preclinical candidates, GPX-002 for Type 1 diabetes and GPX-003 for Type 2 diabetes.
Even with certain advancements in treatment, the quality of life remains highly compromised for many with diabetes. Diabetes gene therapies like those being developed by Genprex could hold the potential to provide long-term effectiveness and completely change the course of the disease – enhancing the quality of life for those living with the disease.
For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
